ALSP Orchid Acquisition Corporation I (ALOR), is a newly organized blank check company formed to pursue an acquisition in healthcare and life sciences. We seek to capitalize on the more than 150 years of collective experience of our management team, board of directors and senior advisors. We intend to focus on opportunities that complement our leaderships’ background and leverage the ability of our leadership team to identify and acquire promising targets.

Our Sponsor

ALSP Orchid Sponsor LLC is an affiliate of Accelerator Life Science Partners (ALSP), a Seattle-based life science investment firm, focused on providing growth capital for early-stage, next generation biotechnology companies. The ALSP management team has established an exceptional track record of identifying disruptive opportunities, advising, building, and successfully exiting biotechnology companies. Leveraging this significant operating, clinical, technical, and transactional experience across all sectors of healthcare, we believe ALSP’s reputation as a trusted partner and our accomplished team of investment professionals and advisors provides a competitive advantage.

Leadership

Our management team, board members and senior advisors have over 150 years of collective experience investing in or operating both publicly traded and privately held life sciences companies. The members of our management team have worked together over many years to successfully build value for investors and are well-positioned to take advantage of the rapid growth in biotechnology company formation.

Thong Q. Le

Chief Executive Officer and Director

Kendall M. Mohler, PhD

Chief Development Officer

Ian A.W. Howes

Chief Financial Officer and Director

Kevin Chow, PhD

Chief Business Officer

Andras T. Forgacs

Chief Operating Officer

Bruce L.A. Carter, PhD

Independent Director & Chairman

Sundar Kodiyalam

Independent Director

Eugene Yeo, PhD, MBA

Independent Director

Stephanie C. Read

Independent Director

Mark W. Hahn

Independent Director & Chair of Audit Committee

Philip Yeo Liat Kok

Senior Advisor

Randall Schatzman, PhD

Senior Advisor

Investment Criteria

We will utilize our extensive network of relationships and connections to proprietary deal flow from top tier venture capital and growth equity firms to source high quality investment opportunities.

Although we may pursue an investment opportunity in any business industry, sector, or geographical location, we have identified the following criteria when evaluating prospective target businesses:

Life science companies in North America and Singapore with a particular emphasis on companies developing assets and next-generation platform technologies with broad applicability.

Companies with a high relative probability of clinical and regulatory success that can provide attractive risk-adjusted returns.

Opportunities with the potential to transform or significantly enhance patient outcomes or address unmet medical needs. Ideal target companies will own first-in-class assets or technologies and have the potential to achieve and maintain long-term competitive advantage.